CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab

Cancer Immunology, Immunotherapy

Volumn 56, Issue 7, 2007, Pages 1107-1117

  DiJoseph, John F ^a   Dougher, Maureen M ^a   Armellino, Douglas C ^a   Kalyandrug, Lyka ^a   Kunz, Arthur ^a   Boghaert, Erwin R ^a   Hamann, Philip R ^a   Damle, Nitin K ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Anti tumor; Calicheamicin; CD20; Immunoconjugates; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CALICHEAMICIN DERIVATIVE; CALICHEAMICIN PLUS RITUXIMAB; CD 22 ANTIBODY PLUS CALICHEAMICIN; CD20 ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG ACTIVITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT;

AMINOGLYCOSIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD20; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; ENEDIYNES; FLOW CYTOMETRY; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, B-CELL; MICE; MICE, NUDE; MICE, SCID;

EID: 34247560840     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0260-5     Document Type: Article

References (38)

1. Damle NK (2004) Tumor-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther 4:1445-1452
2. Bross PF, Beitz J, Chen G et al (2001) Gemtuzumab ozogamicin: approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490-1496
3. Sievers EL, Appelbaum FR, Spielberger RT et al (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678-3684
4. Sievers E, Larson R, Stadmauer E et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254
5. Hamann PR, Hinman LM, Hollander I et al (2002) A potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconj Chem 13:47-58
6. Lee M, Dunne T, Chang C et al. (1992) Calicheamicins, a novel family of antibiotics. 4. Structural elucidations of calicheamicins. J Am Chem Soc 114:985-987
7. Zein N, Sinha A, McGahren W, Ellestad G (1988) Calicheamicin γI: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198-1201
8. Grillo-Lopez A (2003) Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther 3:767-779
9. Ghobrial I, Witzig T (2004) Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology 18:623-630
10. Uchida J, Hamaguchi Y, Oliver JA et al (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659-1669
11. Gaetano ND, Cittera E, Nota R et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581-1587
12. Manches O, Lui G, Chaperot L et al (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101:949-954
13. Hainsworth JD, Litchy S, Burris HA et al (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncology 20:4261-4267
14. Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581
15. DiJoseph JF, Armellino DC, Boghaert E et al (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 103:1807-1814
16. Advani A, Giné E, Gisselbrecht C et al (2005) Preliminary report of a phase 1 study of cmc-544, an antibody-targeted chemotherapy agent, in patients with b-cell non-Hodgkin's lymphoma (NHL). Blood 106(11): abstract No. 230
17. DiJoseph JF, Dougher MM, Kalyandrug LB et al (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 12:242-249
18. DiJoseph JF, Goad ME, Dougher MM et al (2004) Potent and specific anti-tumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 10:8620-8629
19. Flavell DJ, Noss A, Pulford KAF, Ling N, Flavell SU (1997) Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res 57:4824-4829
20. Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU (1995) Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used alone in combination than with either immunotoxin alone. Int J Cancer 62:337-344
21. Hinman LM, Hamann PR, Wallace R, Menendez AT, Dur FE, Upeslacis J (2003) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53:3336-3342
22. Hamann P, Hinman L, Beyer C et al (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconj. Chem 13:40-46
23. DiJoseph JF, Popplewell A, Tickle S et al (2005) Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 54:11-24
24. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49:4906-4912
25. Vangeepuram N, Ong GL, Mattes MJ (1997) Processing of antibodies bound to B-cell lymphomas and lymphoblastoid cell lines. Cancer 80(Suppl):2425-2430
26. Law CL, Cerveny CG, Gordon KA et al (2004) Efficient elimination of B-lineage lymphomas by anti-CD20-Auristatin conjugates. Clin Cancer Res 10:7842-7851
27. Vervoordeldonk SF, Merle PA, van Leeuwen EF, van der Schoot CE, von dem Borne AE, Slaper-Cortenbach IC (1994) Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody. Blood 83:1632-1639
28. Van Den Herik-Oudijk IE, Westerdaal NA, Henriquez NV, Capel PJ, Van De Winkel JG (1994) Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. J Immunol 152:574-585
29. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I (2000) Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 205:55-63
30. Miettinen HM, Matter K, Hunzinker W et al (1992) Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization. J Cell Biol 116:875-888
31. Costello LC, Franklin RB (2005) 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. Mol Cell Biochem 280:1-8
32. Boghaert ER, Khanke K, Sridharan L et al (2006) Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol 28:675-684
33. Harder T, Engelhardt (2004) Membrane domains in lymphocytes-from lipid rafts to protein scaffolds. Traffic 5:265-275
34. Polyak MJ, Tailor SH, Deans JP (1998) Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 161:3242-3248
35. Fujimoto M, Kuwano Y, Wananabe R et al (2006) B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation. J Immunol 176:873-879
36. Gaetano ND, Cittera E, Nota R et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581-1587
37. Cragg MS, Glennie MJ (2004) Antibody specificity controls effector mechanisms of anti-CD20 reagents. Blood 103:2738-2743
38. Cragg MS, Morgan SM, Claude Chan HT et al (2003) Complement-mediated lysis by anti-CD20 mAb correlated with segregation into lipid rafts. Blood 101:1045-1052